期刊文献+

5-氮-2'-脱氧胞苷逆转膀胱癌细胞hepaCAM基因的表达及对其生长的抑制 被引量:1

5-aza-2′-deoxycytidine reverses the expression of hepaCAM mRNA and inhibits the growth of T24 and BIU-87 cells
下载PDF
导出
摘要 目的研究5-氮-2-脱氧胞苷(5-aza-CdR)逆转hepaCAM表达及抑制膀胱癌细胞的生长。方法 MTT法检测细胞增殖;流式细胞术检测细胞凋亡;RT-PCR检测hepaCAM mRNA的表达。结果在T24细胞中,3.0和10.0μmol/L5-aza-CdR药物浓度的抑制率明显高于0.3和1.0μmol/L 5-aza-CdR(P<0.05),在BIU-87细胞中,5.0μmol/L5-aza-CdR药物浓度的抑制率明显高于0.1和0.5μmol/L(P<0.05),并且药物处理细胞72 h的抑制率明显高于24和48 h(P<0.05);5-aza-CdR处理细胞后,T24和BIU-87细胞凋亡数明显增加(P<0.05);并可逆转hepaCAMmRNA表达。结论 5-aza-CdR可使hepaCAM基因重新表达,并通过诱导凋亡而抑制膀胱癌细胞的生长。 Objective To investigate the effect of 5-aza-CdR on expression of hepaCAM mRNA and the inhibition of T24 and BIU-87cell lines.Methods The effects of 5-aza-CdR on cell proliferation of T24 and BIU-87 cell lines were measured by MTT;Flow cytometry was used to examine apoptosis of T24 and BIU-87 cells;RT-PCR was used to detect the expression of hepaCAM in T24 and BIU-87 cell lines with or without 5-aza-CdR treatment.ResultsThe inhibition ratios of 3.0 and 10.0 μmol/L 5-aza-CdR were significantly higher than that of 0.3 and 1.0 μmol/L 5-aza-CdR in T24 cell(P0.05).The inhibition ratio of 5.0 μmol/L 5-aza-CdR was higher than that of 0.1 and 0.5 μmol/L 5-aza-CdR in BIU-87 cell(P0.05).Cell apoptotic rate increased in cells with 5-aza-CdR treatment(P0.05).The expression of hepaCAM mRNA was reversed in T24 and BIU-87 cells after treatment.Conclusions 5-aza-CdR can reverse the expression of hepaCAM mRNA and therefore inhibit the cell growth through inducing apoptosis in bladder cancer tissue.
出处 《基础医学与临床》 CSCD 北大核心 2013年第1期55-59,共5页 Basic and Clinical Medicine
基金 国家自然科学基金(81072086)
关键词 5-AZA-CDR hepaCAM 膀胱癌 细胞凋亡 5-aza-CdR hepaCAM bladder cancer apoptosis
  • 相关文献

参考文献14

  • 1Hanahan D,Weinberg RA. The hallmarks of cancer[J].Cell,2000.57-70.
  • 2Jones PA,Baylin SB. The fundamental role of epigenetic events in cancer[J].Nature Reviews Genetics,2002.415-428.
  • 3Tao L,Wang W,Li L. DNA hypomethylation induced by drinking water disinfection by-produe in mouse and rat kidney[J].Toxicological Sciences,2005.344-352.
  • 4Strahl BD,Allis CD. The language of covalent histone modifications[J].Nature,2000,(6765):41-45.doi:10.1038/47412.
  • 5Tamer E.Fandy. Development of DNA methyltransferase inhibitors for the treatment of neoplastic diseases[J].Current Medicinal Chemistry,2009.2075-2085.
  • 6刘丽乔,罗达亚,付晶晶,龚慧,万福生.5-Aza-CdR对人结肠癌Caco-2细胞系P16基因甲基化状态及其生物学表型的影响[J].基础医学与临床,2011,31(2):161-165. 被引量:6
  • 7J.Goffin,E.Eisenhauer. DNA methltransferase inhibitorsstate of the art[J].Annals of Oncology,2002.1699-1716.
  • 8Zhang QL,Luo CL,Wu XH. HepaCAM induces G1 phase arrest and promotes c-Myc degradation in human renal cell carcinoma[J].Journal of Cellular Biochemistry,2011.2910-2919.
  • 9He Y,Wu X,Luo C. Functional significance of the hepaCAM gene in bladder cancer[J].BMC Cancer,2010.83-89.
  • 10Ehdaie B,Smith SC,Theodorescu D. Personalized medicine in advanced urothelial cancer:when to treat,how to treat and who to treat[J].Can Urol Assoc J,2009.232-236.

二级参考文献18

  • 1Zhang Z, Huettner PC, Nguyen L, et al. Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer[ J]. Oncogene 2006, 25:5436 - 5445.
  • 2Naqvi RA, Hussain A, Raish M, et al. Specific 5'CpG island methylation signatures of FHIT and P16 genes and their potential diagnostic relevance in Indian breast cancer patients[ J]. DNA Cell Biol, 2008, 27:517 - 525.
  • 3Morita S, Iida S, Kato K, et al. The synergistic effect of 5- Aza-2'-deoxycytidine and 5-fluorouracil on drug-resistant tumors[J]. Oncology, 2006, 71:437 -445.
  • 4Herman JG. Epigenetic changes in cancer and preneoplasia [J]. Cold Spring Harbor Symp Quant Biol, 2005, 70:329 - 333.
  • 5Gronbaek K, Hother C, Jones PA. Epigenetic changes in cancer[ J ]. APMIS: Acta Pathol Microbiol Immunol Scand, 2007, 115 : 1039 - 1059.
  • 6Gopisetty G, Ramachandran K, Singal R. DNA methylation and apoptosis[J]. Mol Immunol, 2006, 43:1729 - 1740.
  • 7Zochbauer-Moller S, Fong KM, Virmani AK, et al. Aberrant promoter methylation of multiple genes in non-small cell lung cancers [J]. Cancer Res, 2001, 61:249 -255.
  • 8Hirasawa Y, Arai M, Imazekl F, et al. Methylation status of genes upregulated by demethylating agent 5-Aza-2'-de- oxycytidine in hepatocellular carcinoma [ J ]. Oncology, 2006, 71:77 - 85.
  • 9Wozniak RJ, Klimecki WT, Lau SS, et al. 5-Aza-2'-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation [ J ]. Oncogene, 2007, 26:77-90.
  • 10Benbrahim-Tallaa L, Waterland RA, Dill AL, et al. Tumor suppressor gene inactivation during cadmium-induced malignant transformation of human prostate cells correlates with over expression of de novo DNA methyltransferase [J]. Environ Health Perspect, 2007, 115: 1454 - 1459.

共引文献8

同被引文献11

  • 1Gao Y, Shi Q, Xu S, et al. Cureumin promotes KLF5 pro- teasome degradation through down-regulating YAP/TAZ in bladder cancer ceils [J]. Int J Mol Sci, 2014, 15: 15173- 15187.
  • 2Mayer S, Hirschfeld M, Jaeger M, et al. RON alternative splicing regulation in primary ovarian cancer [J]. Oncol Rep, 2015, 34: 423-430.
  • 3Zhou DH, Li C, Yang LN. Variant RONDeltal60 of the RON receptor tyrosine kinase promotes the growth and inva- sion in vitro and in vivo in gastric cancer cell lines [ J ]. Cancer Cell Int, 2015, 15: 9-17.
  • 4Cheng HL, Liu HS, Lin YJ, et al. Co-expression of RON and MET is a prognostic indicator for patients with transi- tional-ceil carcinoma of the bladder [J]. Br J Cancer, 2005, 92: 1906-1914.
  • 5Yao HP, Zhou YQ, Zhang R, et al. MSP-RON signaling in cancer: pathogenesis and therapeutic potential [J]. Nat Rev Cancer, 2013, 13: 466-481.
  • 6Logan-Collins J, Thomas RM, Yu P, et al. Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers [J]. Cancer Res, 2010, 70: 1130-1140.
  • 7Rodriguez-Mora OG, Lahair MM, Mccubrey JA, et al. Cal- cium/calmodulin-dependent kinase I and calcium/calmodu- lin-dependent kinase kinase participate in the control of cell cycle progression in MCF-7 human breast cancer cells [ J]. Cancer Res, 2005, 65: 5408-5416.
  • 8O'Toole JM, Rabenau KE, Burns K, et al. Therapeutie implications of a human neutralizing antibody to the macro- phage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member [J]. Cancer Res, 2006, 66: 9162-9170.
  • 9Xu XM, Wang D, Shen Q, et al. RNA-mediated gene si- lencing of the RON receptor tyrosine kinase alters oncogen- ic phenotypes of human colorectal carcinoma cells [J]. Oncogene, 2004, 23: 8464-8474.
  • 10何政,吴慧,万荣华,郑军.siRNA沉默CD55基因对胰腺癌BxPC-3细胞生物学行为的影响[J].基础医学与临床,2014,34(7):974-978. 被引量:3

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部